Ocumension Therapeutics (OCUMENSION-B) filed its Monthly Return for the period ended 31 August 2026, indicating no changes to its share capital or treasury-share position during the month. Key data points are as follows:

• Authorised share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, equivalent to total authorised capital of USD 50,000.

• Issued share count stayed at 815.38 million ordinary shares, while treasury shares were unchanged at 20.95 million, leaving total issued shares at 836.33 million.

• The company confirmed that it continued to meet the Main Board’s 25 percent minimum public-float requirement as of 31 August 2026.

Equity incentive activity was limited:

• Employee Stock Option Plan: 13.32 million options outstanding, with no grants, exercises, cancellations or lapses recorded in August.

• 2021 Share Option Scheme: Outstanding options slipped by 64,782 to 45.23 million due to lapses; no new grants or exercises occurred. A total of 65.23 million shares remain available for issue under the scheme.

• 2021 Share Award Scheme: Unvested awards declined marginally after 33,382 awards lapsed, bringing the balance to 16.31 million shares. No new shares were issued and no treasury shares were transferred under the scheme during the month.

The company reported no warrants, convertibles, or other share movements, and reconfirmed that all regulatory conditions for prior issuances have been satisfied.